Recital 8, Regulation (EU) 2024/1206

In forcesince 29 Apr 2024

For the active substances azadirachtin, bupirimate, dithianon, hexythiazox, isoxaben, lime sulphur, orange oil, quinmerac, sodium silver thiosulfate, tau-fluvalinate, tebufenozide, tembotrione and zinc phosphide, as the risk assessment has not yet been finalised by the rapporteur Member States and in light of the time required to complete the remaining steps in each renewal procedure, the duration of the extension of the approval periods should be set at 29 months.